EYPT vs OCUL
EYPT: EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular edema, with the approved product DEXYCU generating minimal revenue. OCUL: Ocular Therapeutix develops sustained-release, bioresorbable hydrogel-based ocular therapies to address chronic and acute eye diseases.
Side-by-side fundamentals
| Metric | EYPT | OCUL | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $5.32 | $11.08 | |
| Market cap as of 2026-08-24 | $459M | $2.4B | |
| PEG as of 2026-08-24 | -0.04 | -0.74 | OCUL lower |
| Net margin as of 2026-08-24 | -10994.7% | -579.1% | OCUL higher |
| Gross margin as of 2026-08-24 | +41.8% | +87.1% | OCUL higher |
| Operating margin as of 2026-08-24 | -11365.2% | -603.0% | OCUL higher |
| ROE as of 2026-08-24 | -135.8% | -59.9% | OCUL higher |
| ROA as of 2026-08-24 | -108.3% | -46.0% | OCUL higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.14 | EYPT lower |
| Revenue growth (YoY) as of 2026-08-24 | -94.6% | -8.1% | OCUL higher |
| Revenue CAGR (3y) SEC XBRL | -8.8% | +0.3% | OCUL higher |
| Beta as of 2026-08-24 | 1.59 | 0.95 | |
| 1-year return as of 2026-08-21 close | -54.1% | -8.7% | OCUL higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.